

Share-based legacy RSU program granted

Novonesis' Board of Directors has following the merger with Chr. Hansen Holding A/S ("Chr. Hansen") today approved the continuation in 2024 of a legacy Chr. Hansen annual short-term incentive program comprising of up to 125,000 restricted share units (RSUs) for around 130 legacy Chr. Hansen key employees below the Executive Management level. Receipt of the RSUs is subject to specified KPIs and criteria supporting performance and retention. The KPIs include personal targets and financial performance indicators (such as: sales revenue, adjusted EBITDA margin, and net working capital in % of sales). Upon grant the RSUs will vest after a period of two (2) years after which participants may receive one (1) Novonesis B share per RSU. The value of the program is up to €6.7m.

Company Announcement no. 12
April 8, 2024

Contact information

Investor Relations

Tobias Bjorklund	+45 3077 8682	tobb@novonesis.com
Anders Enevoldsen	+45 5350 1453	adev@novonesis.com

Novonesis is a global company leading the era of biosolutions.

By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.

**Novozymes A/S, part of
Novonesis Group**
Krogshøjvej 36
2880 Bagsvaerd
Denmark